Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 09, 2021 at 05:13 pm EST
Share
Fulgent Genetics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 227.87 million compared to USD 101.72 million a year ago. Net income was USD 122.52 million compared to USD 46.64 million a year ago. Basic earnings per share from continuing operations was USD 4.13 compared to USD 2.11 a year ago. Diluted earnings per share from continuing operations was USD 3.93 compared to USD 1.98 a year ago.
For the nine months, sales was USD 740.91 million compared to USD 126.73 million a year ago. Net income was USD 403.03 million compared to USD 48 million a year ago. Basic earnings per share from continuing operations was USD 13.79 compared to USD 2.2 a year ago. Diluted earnings per share from continuing operations was USD 13.04 compared to USD 2.07 a year ago.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
FULGENT GENETICS, INC. 
